These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281 [TBL] [Abstract][Full Text] [Related]
4. Associations between lifetime classic psychedelic use and markers of physical health. Simonsson O; Sexton JD; Hendricks PS J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688 [TBL] [Abstract][Full Text] [Related]
5. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]
7. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183 [TBL] [Abstract][Full Text] [Related]
8. Psychedelic microdosing benefits and challenges: an empirical codebook. Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862 [TBL] [Abstract][Full Text] [Related]
9. The prevalence and factors associated with ever perpetrating intimate partner violence by men receiving substance use treatment in Brazil and England: A cross-cultural comparison. Gilchrist G; Radcliffe P; Noto AR; d'Oliveira AF Drug Alcohol Rev; 2017 Jan; 36(1):34-51. PubMed ID: 27709693 [TBL] [Abstract][Full Text] [Related]
10. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460 [TBL] [Abstract][Full Text] [Related]
11. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. Kopra EI; Ferris JA; Winstock AR; Kuypers KP; Young AH; Rucker JJ J Psychopharmacol; 2023 Jul; 37(7):733-748. PubMed ID: 36876583 [TBL] [Abstract][Full Text] [Related]
12. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. Jones GM; Nock MK J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249 [TBL] [Abstract][Full Text] [Related]
13. Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications. O'Callaghan C; Hubik DJ; Dwyer J; Williams M; Ross M J Music Ther; 2020 Jul; 57(3):282-314. PubMed ID: 32227084 [TBL] [Abstract][Full Text] [Related]
14. Pathways between childhood trauma, intimate partner violence, and harsh parenting: findings from the UN Multi-country Study on Men and Violence in Asia and the Pacific. Fulu E; Miedema S; Roselli T; McCook S; Chan KL; Haardörfer R; Jewkes R; Lancet Glob Health; 2017 May; 5(5):e512-e522. PubMed ID: 28395846 [TBL] [Abstract][Full Text] [Related]
15. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231 [TBL] [Abstract][Full Text] [Related]
16. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Lyvers M; Meester M J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892 [TBL] [Abstract][Full Text] [Related]
17. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Garcia-Romeu A; Richards WA Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079 [TBL] [Abstract][Full Text] [Related]
18. The relationships of classic psychedelic use with criminal behavior in the United States adult population. Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G J Psychopharmacol; 2018 Jan; 32(1):37-48. PubMed ID: 29039233 [TBL] [Abstract][Full Text] [Related]
19. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Schartner MM; Carhart-Harris RL; Barrett AB; Seth AK; Muthukumaraswamy SD Sci Rep; 2017 Apr; 7():46421. PubMed ID: 28422113 [TBL] [Abstract][Full Text] [Related]
20. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics. Wilkes R; Roberts DM; Liknaitzky P; Brett J Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]